Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242929 | 1.00 | GFER (0.42) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL242930 | 1.00 | GFER (0.42) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL7431808 | 0.81 | TAAR1 (0.40) | DPP4DPP8DPP9DPP7SLC6A4 | |
| SCHEMBL2267252 | 0.81 | SLC6A4 (0.59) | DPP4DPP8DPP9DPP7SLC6A4 | |
| SCHEMBL9503514 | 0.81 | CA2 (0.41) | ALDH1A1TSHRTDP1MAOASLC6A4 | |
| SCHEMBL8201384 | 0.81 | CYP1A2 (0.41) | CYP3A4DPP4DPP8DPP9DPP7 | |
| SCHEMBL2268272 | 0.81 | LOXL2 (0.43) | LOXL2MAOBMAOADPP4DPP8 | |
| SCHEMBL1972357 | 0.81 | FFAR1 (0.41) | DPP4DPP8DPP9DPP7TAAR1 | |
| SCHEMBL2267270 | 0.81 | TAAR1 (0.40) | DPP4DPP8DPP9DPP7SLC6A4 | |
| SCHEMBL6335 | 0.81 | TAAR1 (0.55) | ALDH1A1CYP3A4MEN1KMT2ASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | disclosed |
| US-5300492-A | Suppressing levels of sex hormones in male or female mammals | TAP PHARMACEUTICALS (US) | 1994-04-05 | — | — | US | disclosed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | GFER 3335/4885ALDH1A1 4350/4885CYP3A4 3758/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | GFER 3335/4885ALDH1A1 4350/4885CYP3A4 3758/4885 |
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | GFER 3887/4885ALDH1A1 1309/4885CYP3A4 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.